🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Cystic Fibrosis

Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis NCT07809867Phase 41 site📍 Genova Istituto Giannina Gaslini · Tests: Elexacaftor, Tezacaftor, Ivacaftor, Ivacaftor (VX-770) A Study of Females With CF Throughout Pregnancy and Post-partum, and Follow up of Their Offspring NCT06797206n/a1 site📍 London Royal Brompton & Harefield NHS Foundation Trust Study of the Prevalence of Active/Passive Smoking and Vaping Among Patients With Cystic Fibrosis NCT07342920n/a1 site📍 Strasbourg University Hospital, Strasbourg, France Estrogen Supplementation and Bone Health in Women With CF NCT05704036Phase 41 site📍 Baltimore Johns Hopkins University · Tests: Transdermal estrogen, Progesterone CF Wellness Program NCT07071324NA3 sites📍 Denver📍 Baltimore📍 Boston Johns Hopkins University · Tests: CF Wellness Program Cellular Markers in Treated or Untreated Non-tuberculous Mycobacterial Respiratory Infection in Patients With Cystic Fibrosis NCT06602869n/a1 site📍 Montpellier University Hospital, Montpellier · Tests: Scheduled visit (V1) Cystic Fibrosis in the Kidney: Monitoring the Effectiveness of Elexacaftor/tezacaftor/ivacaftor in Urine After a Short Pause of Therapy NCT05818319NA1 site📍 Aarhus C University of Aarhus · Tests: 12 hours ETI pause, 36 hours ETI pause, 60 hours ETI pause Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis NCT06747858Phase 213 sites📍 Tucson📍 Little Rock📍 Los Angeles Arcturus Therapeutics, Inc. · Tests: ARCT-032 A Usability Validation of the MuCopilot Mobile Application, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis NCT06132048NA1 site📍 Rouen Ad scientiam · Tests: MuCopilot mobile application Kidney Function in People With Cystic Fibrosis in the Era of HEMT NCT06595420n/a3 sites📍 Birmingham📍 Lebanon📍 Charlottesville University of Virginia Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis NCT07283770Phase 11 site📍 Overland Park Vertex Pharmaceuticals Incorporated · Tests: VX-581, Placebo, D-IVA, TEZ, ELX/TEZ/IVA Sinus Disease in Young Children With Cystic Fibrosis NCT06191640n/a6 sites📍 Aurora📍 Iowa City📍 Kansas City University of California, Los Angeles · Tests: Ivacaftor or elexacaftor/tezacaftor/ivacaftor Skin-interfaced Colorimetric Bifluidic Sweat Sensor Device for the Diagnosis of Cystic Fibrosis (CF) NCT05998629NA1 site📍 Hershey Milton S. Hershey Medical Center · Tests: a skin-interfaced colorimetric bifluidic sweat device with two synchronous channels, Standard of Care laboratory proced… Impact of a Coordinated Dietetic-adapted Physical Activity Program on the Percentage of Lean Body Mass in Adults With Cystic Fibrosis Treated With Elexacaftor-Tezacaftor-Ivacaftor: Multicentre Randomised Controlled Trial NCT06457451NA4 sites📍 Angers📍 Roscoff📍 Tours University Hospital, Tours · Tests: DIAPASOM program GRAnulomatous MAstitis REGistry Study NCT07422870n/a2 sites📍 Düsseldorf📍 Lübeck European Breast Cancer Research Association of Surgical Tri… A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF) NCT06526923Phase 1, Phase 24 sites📍 Kansas City📍 Boston📍 New York Spirovant Sciences, Inc. · Tests: SP-101 and doxorubicin Cohort 1, SP-101 and doxorubicin Cohort 2 Genetics of Insulin and Incretins in Cystic Fibrosis NCT01852448n/a2 sites📍 Philadelphia📍 Philadelphia Children's Hospital of Philadelphia · Tests: Blood or Saliva Sample Collection Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders NCT06147414n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Blood sample Natural History of Noncirrhotic Portal Hypertension NCT02417740n/a1 site📍 Bethesda National Institute of Diabetes and Digestive and Kidney Dis… Maralixibat in Patients With Cystic Fibrosis and Constipation NCT06413368Phase 2, Phase 31 site📍 Los Angeles Children's Hospital Los Angeles · Tests: Maralixibat 9.5 MG/ML [Livmarli] Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function NCT04530383Phase 21 site📍 Kansas City University of Kansas Medical Center · Tests: Metformin Hydrochloride e-Health Program to Prevent Exacerbations in the Cystic Fibrosis Population NCT06313827NA1 site📍 Valencia University of Valencia · Tests: Exercise plus Monitoring Group (TG-2), Exercise plus monitoring and follow-up group (TGF-3), Exercise Group (CG-1) Intestine-lung Axis of Cystic Fibrosis Patients Treated With the Combination Elexacaftor/Tezacaftor/Ivacaftor NCT05937815NA15 sites📍 Bordeaux📍 Grenoble📍 Lille University Hospital, Bordeaux · Tests: Sample collection Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis NCT06057714n/a1 site📍 Chapel Hill University of North Carolina, Chapel Hill · Tests: 19F MRI Study to Enable New Diagnostics for Pulmonary Microbes in People With CF NCT07312734n/a9 sites📍 La Jolla📍 Minneapolis📍 St Louis Chris Goss A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine NCT07274631n/a1 site📍 Reims CHU de Reims · Tests: Non applicable Evaluation of New Device for Beta-adrenergic Sweat Test in the Context of Stratification of Patient With Cystic Fibrosis NCT06836453NA1 site📍 Brussels Cliniques universitaires Saint-Luc- Université Catholique d… · Tests: Sweat stimulation and secretion quantification A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis NCT06559150Phase 251 sites📍 Birmingham📍 Los Angeles📍 Sacramento Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rah… · Tests: Nebulized Ensifentrine Suspension; 3 mg, Nebulized Placebo Solution Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis NCT06413459n/a1 site📍 Milan Ospedale San Raffaele · Tests: Luminex; scRNAsec A Study to Assess the Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis NCT07616375Phase 31 site📍 Yixingcun Haisco Pharmaceutical Group Co., Ltd. · Tests: HSK31858, tablet
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy